Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLianxuan LiuYHYongxian HuJFJingjing Feng

Discussion

Loading...

Member takes

Overview

Phase II trial shows 90.9% overall survival with rituximab and CAR-T in high-risk large B-cell lymphoma, indicating a potential shift in treatment approach.

Key Points

  • 90.9% overall survival rate observed at 3 years in patients with high-risk large B-cell lymphoma.
  • Among 28 patients receiving CAR-T, 96.4% achieved complete response after treatment.
  • Single-arm phase II clinical trial assessed sequential treatment involving rituximab and CAR-T therapy.
  • Adverse events were manageable, highlighting the safety profile of targeted therapy in high-risk patients.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d58ahttps://doi.org/10.1182/blood-2025-1940
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  2. 2CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  3. 3A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation2025
  4. 4Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  5. 5A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma2025 · 5 citations